Letter

Genetics consortiums can offer views facilitating best practice in Alzheimer's disease

BMJ 1998; 317 doi: 10.1136/bmj.317.7156.471 (Published 15 August 1998)
Cite this as: BMJ 1998;317:471.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Simon Lovestone, Chair of United Kingdom Alzheimer's Disease Genetics Consortium
  1. Institute of Psychiatry, London SE5 8AF

    EDITOR—Alzheimer's disease is often taken as an example of a disorder for which the impact of the new genetics will be met, 1 2 and it was with this in mind that the United Kingdom Alzheimer's Disease Genetics Consortium was formed. Members of the consortium are clinicians involved in both genetics and dementia care, academics, members of lay organisations, and representatives from pharmaceutical research; they meet to consider the consequences of the growing understanding of genetics in Alzheimer's disease. Through …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular